Utilization of microarrayed compound screening (μARCS) to identify inhibitors of p56lck tyrosine kinase

被引:4
|
作者
Freiberg, G
Wilkins, J
David, C
Kofron, J
Jia, Y
Hirst, GC
Burns, DJ
Warrior, U [1 ]
机构
[1] Abbott Labs, Global Pharmaceut Res Dev, Abbott Pk, IL 60064 USA
[2] Abbott Biores Ctr, Worcester, MA USA
关键词
protein tyrosine kinases; drug discovery; microarrayed compound screening (mu ARCS); high-throughput screening;
D O I
10.1177/1087057103259667
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Protein tyrosine kinases play critical roles in cell signaling and are considered attractive targets for drug discovery. The authors have applied muARCS (microarrayed compound screening) technology to develop a high-throughput screen for finding inhibitors of the p56(lck) tyrosine kinase. Initial assay development was performed in a homogeneous time-resolved (LANCE(TM)) format in 96-well microplates and then converted into the gel-based muARCS format. The muARCS methodology is a well-less screening format in which 8640 compounds are arrayed on a microplate-sized piece of polystyrene and subsequently assayed by placing reagents cast in agarose gels in contact with these compound sheets. A blotting paper soaked with adenosine triphosphate is applied on the gel to initiate the kinase reaction in the gel. Using this screening methodology, 300,000 compounds were screened in less than 40 h. Substantial reagent reduction was achieved by converting this tyrosine kinase assay from a 96-well plate assay to muARCS, resulting in significant cost savings.
引用
收藏
页码:12 / 21
页数:10
相关论文
共 50 条
  • [1] The development of novel and selective p56lck tyrosine kinase inhibitors
    Bullington, JL
    Cameron, JC
    Davis, JE
    Dodd, JH
    Harris, CA
    Henry, JR
    Pellegrino-Gensey, JL
    Rupert, KC
    Siekierka, JJ
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1998, 8 (18) : 2489 - 2494
  • [2] Inhibition of p56lck tyrosine kinase by isothiazolones
    Trevillyan, JM
    Chiou, XG
    Ballaron, SJ
    Tang, QM
    Buko, A
    Sheets, MP
    Smith, ML
    Putman, CB
    Wiedeman, P
    Tu, N
    Madar, D
    Smith, HT
    Gubbins, EJ
    Warrior, UP
    Chen, YW
    Mollison, KW
    Faltynek, CR
    Djuric, SW
    ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 1999, 364 (01) : 19 - 29
  • [3] Microarrayed compound screening (μARCS) to identify activators and inhibitors of AMP-activated protein kinase
    Anderson, SN
    Cool, BL
    Kifle, L
    Chiou, W
    Egan, DA
    Barrett, LW
    Richardson, PL
    Frevert, EU
    Warrior, U
    Kofron, JL
    Burns, DJ
    JOURNAL OF BIOMOLECULAR SCREENING, 2004, 9 (02) : 112 - 121
  • [4] PURIFICATION OF THE LSTRA TYROSINE PROTEIN-KINASE (P56LCK)
    VANTAN, H
    FISCHER, S
    FAGARD, R
    EUROPEAN JOURNAL OF BIOCHEMISTRY, 1988, 172 (01): : 67 - 72
  • [5] Requirement for p56lck tyrosine kinase activation in Th subset differentiation
    Yamashita, M
    Hashimoto, K
    Kimura, M
    Kubo, M
    Tada, T
    Nakayama, T
    INTERNATIONAL IMMUNOLOGY, 1998, 10 (05) : 577 - 591
  • [6] THE LYMPHOCYTE-SPECIFIC TYROSINE PROTEIN-KINASE P56LCK
    ABRAHAM, N
    VEILLETTE, A
    CANCER INVESTIGATION, 1991, 9 (04) : 455 - 463
  • [7] Requirement for p56lck (Lck) tyrosine kinase activation in the T helper subset differentiation.
    Yamashita, M
    Kubo, M
    Nakayama, T
    FASEB JOURNAL, 1998, 12 (05): : A938 - A938
  • [8] ANALYSIS OF THE TRANSFORMING PROPERTIES OF P56LCK, A NOVEL TYROSINE PROTEIN-KINASE
    VORONOVA, AF
    SEFTON, BM
    JOURNAL OF CELLULAR BIOCHEMISTRY, 1987, : 208 - 208
  • [9] Requirement for tyrosine kinase p56lck for thymic development of transgenic γδ T cells
    Penninger, J.
    Kishihara, K.
    Molina, T.
    Wallace, V.A.
    Timms, E.
    Hedrick, S.M.
    Mak, T.W.
    Science, 1993, 260 (5106)
  • [10] Homogeneous assay for tyrosine kinase:: Use of bacteriophage antibody conjugates in an assay for p56lck kinase
    Patel, J
    Stanley, CJ
    Wilson, SM
    CLINICAL CHEMISTRY, 2002, 48 (10) : 1860 - 1862